山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (10): 3-8.doi: 10.6040/j.issn.1671-7554.0.2018.1028
中国医师协会检验医师分会妇科肿瘤检验医学专家委员会
中图分类号:
| [1] Collins Y, Holcomb K, Chapman-Davis E, et al. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology[J]. Gynecol Oncol, 2014, 133(2): 353-361. [2] Bourla AB, Zamarin D. Immunotherapy: new strategies for the treatment of gynecologic malignancies[J]. Oncology(Williston Park), 2016, 30(1): 59-66, 69. [3] Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer[J]. Clin Chim Acta, 2013, 415: 341-345. doi: 10.1016/j.cca.2012.10.058. [4] 邹瑟音,夏勇,梁思宇,等. 联合检测肿瘤标志物在卵巢癌诊断中的临床应用评价[J].检验医学与临床, 2014, 11(23): 3316-3317. [5] 张宏兴. 血清CA125, CA199, CEA, AFP联监在卵巢癌诊断中应用价值研究[J].中国妇幼保健,2013, 25(3):4247-4249. ZHANG Hongxing. Study on application value of joint detection of serum CA125, CA19-9, CEA, and AFP in diagnosis of ovarian cancer [J]. Maternal and Child Health Care of China, 2013, 25(3): 4247-4249. [6] Rein BJ, Gupta S, Dada R, et al. Potential markers for detection and monitoring of ovarian cancer[J]. J Oncol, 2011, 2011: 475983. doi: 10.1155/2011/475983. [7] Buamah P. Benign conditions associated with raised serum CA-125 concentration[J]. J Surg Oncol, 2000, 75(4): 264-265. [8] Buamah PK, Skillen AW. Serum CA 125 concentrations in patients with benign ovarian tumours[J]. J Surg Oncol, 1994, 56(2): 71-74. [9] Niloff JM, Klug TL, Schaetzl E, et al. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix[J]. Am J Obstet Gynecol, 1984, 148(8): 1057-1058. [10] Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer[J]. Clin Chim Acta, 2013, 415: 341-345. doi: 10.1016/j.cca.2012.10.058. [11] Tate S, Hirai Y, Takeshima N, et al. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma[J]. Gynecol Oncol, 2005, 96(1): 143-149. [12] Le T, Faught W, Hopkins L, et al. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer[J]. J Obstet Gynaecol Can, 2008, 30(8): 665-670. [13] Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40[J]. J Clin Oncol, 2004, 22(16): 3330-3339. [14] Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range[J]. J Clin Oncol, 2005, 23(36): 9338-9343. [15] Rustin GJ, Nelstrop AE, Mcclean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125[J]. J Clin Oncol, 1996, 14(5): 1545-1551. [16] Kirchhoff C. Molecular characterization of epididymal proteins[J]. Rev Reprod, 1998, 3(2): 86-95. [17] Montagnana M, Danese E, Giudici S, et al. HE4 in ovarian cancer: from discovery to clinical application[J]. Adv Clin Chem, 2011, 55: 1-20. [18] Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol, 2008, 108(2): 402-408. [19] Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence[J]. Gynecol Oncol, 2008, 110(3): 374-382. [20] Drapkin R, Von Horsten HH, Lin Y, et al. Human epididymis protein 4(HE4)is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J]. Cancer Res, 2005, 65(6): 2162-2169. [21] Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?[J]. Arch Gynecol Obstet, 2013, 288(1): 167-172. [22] Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass[J]. Am. J Obstet Gynecol, 2010, 203(3): 228.e1-228.e6. doi: 10.1016/j.ajog.2010.03.043. [23] Tian, Y, Wang C, Cheng L, et al. Determination of reference intervals of serum levels of human epididymis protein 4(HE4)in Chinese women [J] J Ovarian Res, 2015. 8(1): 72. [24] Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer[J]. JAMA, 2002, 287(13): 1671-1679. [25] Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer[J]. J Clin Oncol, 2010, 28(13): 2159-2166. [26] Pal MK, Rashid M, Bisht M. Multiplexed magnetic nanoparticle-antibody conjugates(MNPs-ABS)based prognostic detection of ovarian cancer biomarkers, CA-125, beta-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance(SPR)analysis[J]. Biosens Bioelectron, 2015, 73: 146-152. doi: 10.1016/j.bios.2015.05.051. [27] Richardson MA. Complementary and alternative therapy use in gynecologic oncology: implications for clinical practice[J]. Gynecol Oncol, 2002, 84(3): 360-362. [28] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [29] Du PL, Wu KS, Fang JY, et al. Cervical Cancer Mortality Trends in China, 1991-2013, and Predictions for the Future[J]. Asian Pac J Cancer Prev, 2015, 16(15): 6391-6396. [30] Ohara K, Tanaka Y, Tsunoda H, et al. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging[J]. Obstet Gynecol, 2002, 100(4): 781-787. [31] Takeda M, Sakuragi N, Okamoto K, et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix[J]. Acta Obstet Gynecol Scand, 2002, 81(5): 451-457. [32] Gaarenstroom KN, Kenter GG, Bonfrer JM, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?[J]. Gynecol Oncol, 2000, 77(1): 164-170. [33] Chou CY, Wang ST, Kuo HC, et al. Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer[J]. Cancer, 1994, 74(9): 2497-2501. [34] Bolli JA, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix[J]. Gynecol Oncol, 1994, 55(2): 169-173. [35] Lo Gerfo P, Krupey J, Hansen HJ. Demonstration of an antigen common to several varieties of neoplasia[J]. N Engl J Med, 1971, 285(3): 138-141. [36] Borras G, Molina R, Xercavins J, et al. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix[J]. Gynecol Oncol, 1995, 57(2): 205-211. [37] Kjaer SK, Van Den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus(HPV)as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study[J]. BMJ, 2002, 325(7364): 572. [38] Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities[J]. J Natl Cancer Inst, 2005, 97(14): 1066-1071. [39] Walker JL, Wang SS, Schiffman M, et al. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study(ALTS)[J]. Am J Obstet Gynecol, 2006, 195(2): 341-348. [40] 桑勇先. CA125的研究进展[J]. 中国医药指南,2013,11(12): 451-453. [41] Liu L, Xu X, Jia L, et al. Primary fallopian tube carcinoma-a retrospective analysis of 66 cases[J]. Eur J Gynaecol Oncol, 2015, 36(2): 161-167. [42] Kalampokas E, Sofoudis C, Boutas I, et al. Primary fallopian tube carcinoma: a case report and mini-review of the literature[J]. Eur J Gynaecol Oncol, 2014, 35(5): 595-596. [43] Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use[J].Int J Gynecol Cancer, 2005, 15(5): 679-691. [44] Levy T, Weiser R, Boaz M, et al. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients[J]. Gynecol Oncol, 2013, 129(1): 165-168. [45] Papadimitriou CA, Markaki S, Lianos E, et al. Clinicopathological features of primary fallopian tube carcinoma: a single institution experience[J]. Eur J Gynaecol Oncol, 2009, 30(4): 389-395. [46] Rosen AC, Ausch C, Klein M, et al. p53 expression in fallopian tube carcinomas[J]. Cancer Lett, 2000, 156(1): 1-7. [47] Halon A, Rabczynski J. PCNA and laminin as prognostic factors in primary Fallopian tube carcinoma[J]. Folia Morphol, 2003, 62(4): 475-478. [48] Wang F, Sun GP, Zou YF, et al. Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features[J]. Folia Histochem Cytobiol, 2011, 49(3): 389-397. [49] Chhabra S, Bhavani MandDeshpande A. Trends of vulvar cancer[J]. J Obstet Gynaecol, 2014, 34(2): 165-168. [50] Del Pino M, Rodriguez-Carunchio LandOrdi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma[J]. Histopathology, 2013, 62(1): 161-175. |
| [1] | 山东省药学会. 药物临床试验用药品管理山东专家共识[J]. 山东大学学报 (医学版), 2026, 64(4): 8-13. |
| [2] | 中国医师协会骨科医师分会智能骨科学组,中华预防医学会脊柱疾病预防与控制专业委员会脊柱脊髓损伤疾病预防与控制学组. 人工智能脊柱退变影像学测量位点与标注专家共识(2025)[J]. 山东大学学报 (医学版), 2026, 64(2): 1-10. |
| [3] | 机器人辅助经椎间孔腰椎椎体间融合术手术技术专家组. 机器人辅助经椎间孔腰椎椎体间融合术专家共识[J]. 山东大学学报 (医学版), 2026, 64(2): 11-21. |
| [4] | 赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85. |
| [5] | 杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110. |
| [6] | 山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5. |
| [7] | 山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16. |
| [8] | 华裔骨科学会骨科康复专业委员会. 全膝关节置换术后膝关节功能加速康复专家共识[J]. 山东大学学报 (医学版), 2024, 62(10): 48-61. |
| [9] | 执笔专家: 班艳丽, 赵颖, 李桦, 刘薇, 荣风年, 赵淑萍, 崔保霞. 剖宫产子宫瘢痕妊娠实用临床分型诊治专家共识[J]. 山东大学学报 (医学版), 2023, 61(11): 1-10. |
| [10] | 王稳,董绍华,田翔宇,崔秀娟. 盆腹腔多发脾种植误诊为妇科肿瘤1例[J]. 山东大学学报 (医学版), 2020, 1(9): 116-118. |
| [11] | 官燕飞,陈志强,袁春雷,彭建明,米贤军,刘君,陈昂,袁斌,刘子成. 外周血循环肿瘤细胞、糖类抗原153、糖类抗原125、癌胚抗原检测对105例乳腺导管原位癌或伴微小浸润癌的诊断价值[J]. 山东大学学报 (医学版), 2020, 58(2): 72-78. |
| [12] | 胡佳林,吕家驹,谈月清,管明德,毛昌琳,丁森泰. 睾丸肿瘤86例临床分析[J]. 山东大学学报 (医学版), 2019, 57(4): 77-83. |
| [13] | 曹冬焱,毕晓宁,沈铿. 抗苗勒氏管激素在妇科肿瘤领域的应用前景[J]. 山东大学学报 (医学版), 2018, 56(5): 8-12. |
| [14] | 中国医师协会检验医师分会肺癌检验医学专家委员会. 肺癌实验室诊断专家共识[J]. 山东大学学报 (医学版), 2018, 56(10): 9-17. |
| [15] | 高春芳,黄晨军. 肝内胆管细胞癌肿瘤标志物研究与临床应用进展[J]. 山东大学学报 (医学版), 2018, 56(10): 24-30. |
|
||
